

EXTENDED REFERENCES (Supplementary File)

1. Dicker RC, Ordin DL, Han LF et al. Introducing the Medicare quality of care surveillance system. Baltimore: Health Care Financing Administration; 1997.
2. American Heart association. 1998 Heart and stroke statistical update. Dallas: the Association; 1998.
3. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: A study of all incident cases in Olmsted County, Minnesota, in 1991. *Circulation* 1998;98: 2282-9..
4. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. *J Am Coll Cardiol* 1993; 22 (4A): 6A-13A.
5. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure trials. *Arch Intern Med* 2002; 162: 1682-8.
6. Brown AM, Cleland JG. Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. *Eur Heart J* 1998; 19: 1063–9.
7. Gambassi G, Forman DE, Lapane KL *et al.*, Management of heart failure among very old persons living in long-term care: has the voice of trials spread? The SAGE Study Group. *Am Heart J* 2000; 139: 85–93.
8. Krumholz HM, Parent EM, Tu N *et al.*, Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. *Arch Intern Med* 1997; 157: 99–104.
9. Chin MH and Goldman L. Factors contributing to the hospitalization of patients with congestive heart failure. *Am J Public Health* 1997; 87: 643–648.
10. Havranek EP, Masoudi FA, Westfall KA, Wolfe P, Ordin DL, Krumholz HM. Spectrum of heart failure in older patients: Results from the National Heart Failure Project. *Am Heart J* 2002; 143: 412-7
11. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. *J Am Coll Cardiol* 2003; 42: 1226-1233.
12. Zhang JX, Rathouz PJ, Chin MH. Comorbidity and the concentration of healthcare expenditures in older patients with heart failure. *J Am Geriatr Soc* 2003; 51: 476-482
13. Mueller T, Gegenhuber A, Poelz W et al. Diagnostic accuracy of B-type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. *Heart* 2005; 91: 606-12.
14. Zaphiriou A, Robb S, Murray-Thomas T et al. The diagnostic accuracy of plasma BNP and NT proBNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study. *Eur J Heart Fail.* 2005; 7: 537-41.
15. Weber KT, Wilson JR, Janicki JS, Likoff MJ. Exercise testing in the evaluation of the patient with chronic cardiac failure. *Am Rev Respir Dis* 1984;129:S60-2
16. Salpeter SS, Ormiston T, Salpeter EE. Cardioselective beta-blockers in patients with reactive airways disease: a meta-analysis. *Ann Intern Med* 2002;137: 715-25.
17. Kotlyar E, Keogh AM, MacDonald PS et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. *J Heart Lung Transplant* 2002;21: 1290-5.
18. Cormican LJ, Williams A. Sleep disordered breathing and its treatment in congestive heart failure. *Heart* 2005;91: 1265-1270.
19. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guidelines update for the diagnosis and management of chronic heart failure in the adult: summary article: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure. *J Am Coll Cardiol* 2005;46: 1116-43.
20. Sleep Heart Health Study, F.J. Nieto, T.B. Young, K.L. Bonnie, E. Shahar, J.M. Samet, S. Redline, R.B. D'Agostino, A.B. Newman, M. Lebowitz and T.C. Pickering, Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. *J. Am. Med. Assoc.* 2000; 283:1829–1836.

21. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. *New Engl. J. Med* 2000; 342: 1378–84
22. Dark DS, Pingleton SK, Kerby GR, et al. Breathing pattern abnormalities and arterial oxygen desaturation during sleep in the congestive heart failure syndrome. Improvement following medical therapy. *Chest* 1987; 91: 833–836
23. Solin P, Bergin P, Richardson M, Kaye DM, Walters EH, Naughton MT. Influence of pulmonary capillary wedge pressure on central apnea in heart failure. *Circulation* 1999; 99: 1574-1579.
24. Javaheri S, Corbett WS. Association of low P_{CO_2} with central sleep apnea and ventricular arrhythmias in ambulatory patients with stable heart failure. *Ann. Intern. Med.* 1998; 128: 204–7.
25. Hanly PJ, Zuberi-Khokhar NS. Increased mortality associated with Cheyne–Stokes respiration in patients with congestive heart failure. *Am. J. Respir. Crit. Care Med* 1996; 153: 272–6
26. Lanfranchi PA, Braghiroli A, Bosimini E, Mazzuero G, Colombo R, Donner CF, Gianuzzi P. Prognostic value of nocturnal Cheyne–Stokes respiration in chronic heart failure. *Circulation* 1999; 99: 1435–1440.
27. Bradley TD, Floras JS. Sleep apnea and heart failure: part 1: Obstructive sleep apnea. *Circulation* 2003;107: 1671-8.
28. Ferrier K, Campbell A, Yee B et al. Sleep-disordered breathing occurs frequently in stable outpatients with congestive heart failure. *Chest* 2005; 128: 2116-22.
29. American Academy of Sleep Medicine Task Force. Sleep related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. *Sleep* 1999;22: 667-89.
30. Lattimore JD, Celermajor DS, Wilcox J. Obstructive sleep apnea and cardiovascular disease. *J Am Coll Cardiol* 2003;41: 1429-37.
31. Kaneko Y, Floras JS, Usui K *et al.*, Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. *N Engl J Med* 2003; 348: 1233–41
32. Mansfield DR, Gollogly NC, Kaye DM et al. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. *Am J Resp Crit Care Med* 2004;169: 361-6.
33. Usui K, Bradley TD, Spark J et al. Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure. *J Am Coll Cardiol* 2005; 45: 2008-11.
34. Ryan CM, Usui K, Floras JS, Bradley TD. Effect of continuous positive airway pressure on ventricular ectopy in heart failure patients with obstructive sleep apnea. *Thorax* 2005;60: 781-5.
35. Naughton MT, Benard DC, Liu PP, Rutherford R, Rankin F, Bradley TD. Effects of nasal CPAP on sympathetic activity in patients with heart failure and central sleep apnea. *Am. J. Respir. Crit. Care Med* 1995; 152: 473–479;
36. Naughton MT, Liu PP, Benard DC, Goldstein RS, Bradley TD. Treatment of congestive heart failure and Cheyne–Stokes respiration during sleep by continuous positive airway pressure. *Am. J. Respir. Crit. Care Med* 1995; 151: 92–97.
37. Krachman SL, Crocetti J, Berger TJ, Chatila W, Eisen HJ, D'Alonzo GE. Effects of nasal continuous positive airway pressure on oxygen body stores in patients with Cheyne–Stokes respiration and congestive heart failure. *Chest* 2003; 123: 59-66.
38. Granton J, Naughton M, Bernard D et al. CPAP improves inspiratory muscle strength in patients with heart failure and central sleep apnea. *Am J resp Crit Care Med* 1996;153:277-82.
39. Sin DD, Logan AG, Fitzgerald FS et al. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne–Stokes Respiration. *Circulation* 2000; 102: 61-6.
40. Bradley TD, Logan AG, Kimoff RJ et al. for the CANPAP Investigators. Continuous airway pressure for central sleep apnea and heart failure. *N Engl J Med* 2005;353: 2025-33.

41. Teschler H, Döhring J, Wang YM, Berthon-Jones M. Adaptive pressure support servo-ventilation. A novel treatment for Cheyne–Stokes respiration in heart failure. *Am. J. Respir. Crit. Care Med* 2001; 164: 614–9.
42. Francis DP, Willson K, Davies CL, Coats AJ, Piepoli M. Quantitative general theory for periodic breathing in chronic heart failure and its clinical implications. *Circulation* 2000; 102: 2214–21
43. Hanly PJ, Millar TW, Steljes DG, Baert R, Fraix MA, Kryger MH. The effect of oxygen on respiration and sleep in patients with congestive heart failure. *Ann. Intern. Med* 1989; 111: 777–82.
44. Franklin KA, Eriksson P, Sahlin C, Lundgren R. Reversal of central sleep apnea with oxygen. *Chest* 1997; 111: 163–9.
45. Staniforth AD, Kinnear WJ, Starling R, Hetmanski DJ, Cowley AJ. Effect of oxygen on sleep quality, cognitive function and sympathetic activity in patients with chronic heart failure and Cheyne–Stokes respiration. *Eur. Heart J* 1998; 19: 922–8.
46. Krachman SL, D'Alonzo GE, Berger TJ, Eisen JE, Comparison of oxygen therapy with nasal continuous positive airway pressure on Cheyne–Stokes respiration during sleep in congestive heart failure. *Chest* 1999; 116: 1550–7
47. Javaheri S, Parker TJ, Wexler L, Liming JD, Lindower P, Roselle GA. Effect of theophylline on sleep-disordered breathing in heart failure. *New Engl. J. Med* 1996; 335: 562–7.
48. Garrigue S, Bordier P, Jais P, Shah DC, Hocini M, Raheison C, Tunon De Lara M, Haissaguerre M, Clementy J. Benefit of atrial pacing in sleep apnea syndrome. *New Engl. J. Med* 2002; 346: 404–12.
49. Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella of cardiovascular risk profile. *J Am Coll Cardiol* 2001; 38: 1782–7.
50. Hillege HL, Girbes AR, de Kam PJ *et al.*, Renal function, neurohormonal activation, and survival in patients with chronic heart failure. *Circulation* 2000; 102: 203–10.
51. Ezekowitz J, McAlister FA, Humphries KH *et al* for the APPROACH Investigators. The association among renal insufficiency, pharmacotherapy and outcomes in 6,427 patients with heart failure and coronary artery disease. *J Am Coll Cardiol* 2004;44: 1587–92.
52. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. *J Am Coll Cardiol* 2000; 35: 681–9.
53. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. *Ann Intern Med* 2003; 138:917–24.
54. Philbin EF, Santella RN, Rocco TA, Jr. Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction. *J Am Geriatr Soc* 1999;47:302–8.
55. Erdmann E, Lechat P, Verkenne P, *et al.* Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol on high-risk patient groups with chronic heart failure. *Eur J Heart Fail* 2001; 3:469–79.
56. Cice G, Ferrara L, D'Andrea A, *et al.* Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. *J Am Coll Cardiol* 2003; 41:448–54.
57. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. *N Engl J Med.* 2004; 351:543–5.
58. Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. *Am Heart J* 2004;148: 971–8.
59. Masoudi FA, Cross CP, Wang Y *et al.* Adoption of spironolactone for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998–2001. *Circulation* 2005;112: 39–47.
60. Katz SD. Mechanisms and treatment of anemia in chronic heart failure. *Congest Heart Fail* 2004; 10: 243–7.
61. Androne AS, Katz SD, Lund L *et al.*, Hemodilution is common in patients with advanced heart failure. *Circulation* 2003; 107: 226–9.

62. Adams KF, Patterson JH, Pina I *et al.*, STAMINA-HFP (Study of Anemia in a Heart Failure Population) registry: rationale, design, and patient characteristics, *J Card Failure* 2003; 9: 73
63. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure, *J Am Coll Cardiol* 2002; 39:1780–86.
64. McMurray, J.J., Lang, C.C., Swedberg, K., Ostergren, J., Granger, C.B., Michelson, E., Young, J.B., Olofsson, B., Dunlap, M., Yusuf, S. & Pfeffer, M.A. Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Program (CHARM). *Journal of the American College of Cardiology* 2004; 43: 197A.
65. Silverberg DS, Wexler D, Sheps D *et al.*, The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study, *J Am Coll Cardiol* 2001; 37:1775–80.
66. Mancini DM, Katz SD, Lang CC, Lamanca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure, *Circulation* 2003; 107: 294–9.
67. Almeida OP, Flicker L. The mind of a failing heart: a systematic review of the association between congestive heart failure and cognitive functioning. *Intern Med J* 2001;31: 290-5.
68. Zuccala G, Pedone C, Cesari M *et al.* The effects of cognitive impairment on mortality among hospitalized patients with heart failure. *Am J Med* 2003;115: 97-103.
69. Konstam V, Moser DK, De Jong MJ. Depression and anxiety in heart failure. *J Card Fail* 2005;11: 455-63.
70. Thomas SA, *et al.* Depression in patients with heart failure: physiologic effects, incidence, and relation to mortality. *AACN Clin Issues* 2003; 14(1):3–12.
71. Sullivan M, *et al.* Depression-related costs in heart failure care. *Arch Intern Med* 2002; 162:1860–6.
72. Guck TP, Elsasser GN, Kavan MG, Barone EJ. Depression and congestive heart failure. *Congest Heart Fail* 2003; 9:163-9.
73. Jacob S, Sebastian JC, Abraham G. Depression and congestive heart failure: are antidepressants underutilized? *Eur J Heart Fail* 2003;5: 399-400.
74. Feenstra J, Grobbee DE, Mosterd A, Stricker BH. Adverse cardiovascular effects of NSAIDs in patients with congestive heart failure. *Drug Saf* 1997; 17: 166–80.
75. Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. *Drugs* 2003;63: 525-34.
76. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. *Arch Intern Med* 2000; 160: 777–84.
77. Solomon SD, McMurray JJ, Pfeffer MA *et al.* Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Engl J Med* 2005;352: 1071-80.
78. Teo KK, Yusuf S, Pfeffer M *et al.*, Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. *Lancet* 2002; 360: 1037–43.
79. Nguyen KN, Aurnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril study II (CONSENSUS II). *Am J Cardiol* 1997;79: 115-9.
80. Meune C, Mahe I, Mourad JJ *et al.* Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: dose-mediated deleterious effect. *Eur J Heart Failure* 2003;5: 271-9.
81. Cleland JG, Ghosh J, Fremantle N *et al.* Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy. *Eur J Heart Fail* 2004; 6: 501-8.

82. Hochberg MC, Lebowitz MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. *Semin Arthritis Rheum* 2005; 34: 819-36.
83. Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad spectrum anti-inflammatory approaches. *Am J Cardiol* 2005; 95 (11A): 17C-23C.
84. Masoudi FA, Baillie CA, Wang Y et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. *Arch Intern Med* 2005;165: 2069-76.
85. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. *N Engl J Med* 1995; 333: 1190-5.
86. Cleland JG, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. *Eur J Heart Fail* 1999; 1: 211-7